Optical imaging of pancreas cancer organoids for drug development and personalized treatment
胰腺癌类器官的光学成像用于药物开发和个性化治疗
基本信息
- 批准号:9769226
- 负责人:
- 金额:$ 24.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAdjuvantArchitectureBiopsyBiopsy SpecimenCaringCell CommunicationCellsCessation of lifeClinical TrialsDataDevelopmentDevelopment PlansDimensionsDiseaseDrug Delivery SystemsDrug MonitoringDrug ScreeningDrug ToleranceDrug resistanceEarly DiagnosisEnzymesFibroblastsFluorescenceGoalsGoldHumanImageImaging technologyIndividualMalignant NeoplasmsMalignant neoplasm of pancreasMass Spectrum AnalysisMetabolicModelingMonitorMorbidity - disease rateMusNADHNeoplasm MetastasisOperative Surgical ProceduresOpticsOrganoidsPancreatic Ductal AdenocarcinomaPatientsPharmaceutical PreparationsPopulation DensityPrediction of Response to TherapyPrimary NeoplasmProgression-Free SurvivalsRegimenSamplingStromal CellsStromal NeoplasmSuspensionsSystemTechniquesTechnologyTestingTimeToxic effectTreatment EfficacyTumor Volumebasecell typechemotherapycohortdrug developmentdrug response predictionimaging approachimprovedimproved outcomein vivoinhibitor/antagonistmetabolic imagingmortalitymouse modelneoplastic cellnovelnovel therapeuticsoptical imagingoutcome forecastpatient responsepersonalized medicineresponsesingle cell analysisstandard measurestandard of carethree dimensional cell culturetooltreatment planningtumor
项目摘要
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and poorly understood disease that has the
worst prognosis of all cancers (5 year survival of 7%), with more than 40,000 deaths per year in the US. Standard-
of-care treatment for PDAC includes surgery and chemotherapy. Many patients receive chemotherapy after
surgery (“adjuvant treatment”), to improve progression-free survival. About 45-55% of patients present with
metastatic disease and immediately begin chemotherapy if tolerated. Unfortunately, there are significant
toxicities associated with chemotherapy, and there are no tools to determine whether a patient will benefit from
a more toxic versus a less toxic drug. Additionally, there is no rational system to match each patient with the
most promising new drug for their cancer. Finally, there are few effective drugs for PDAC, and therefore a
demand for accelerated drug development. Thus, there is a critical need to improve the care of PDAC patients
through reduced toxicities, rational treatment planning, and new drug development.
The goal of this proposal is to develop novel cellular-level imaging technologies to predict treatment response
in individual PDAC patients, using macro-suspensions of the patients’ tumors maintained in a 3D culture
(“organoids”). This non-invasive optical metabolic imaging (OMI) approach exploits the intrinsic fluorescence
intensity and lifetime of the metabolic co-enzymes NADH and FAD to image drug response on a single-cell level
across all cells in the intact 3D sample. This single-cell analysis allows for heterogeneous drug response to be
monitored over a treatment time-course in tumor cells and stromal cells. This is important for assessing treatment
efficacy in the highly heterogeneous and stromal micro-environment of PDAC. The use of primary tumor
organoids derived from the patients’ own tumor also maintains the cell-cell communication, 3D architecture, and
tumor-stromal interactions that are critical to accurately assess drug response. Our preliminary data indicate that
OMI in primary PDAC organoids (1) accurately predicts in vivo drug response in mice, and (2) can identify drugs
that effectively target tumor fibroblasts for stromal re-organization and improved drug delivery. We have also
established feasibility for human testing in 6 PDAC patients. This novel platform provides great potential for (1)
rapidly testing new drug regimens on relevant patient samples, thus accelerating PDAC drug development, and
(2) providing individualized drug screens to identify the most effective and least toxic treatment for each patient.
This proposal will test the hypothesis that OMI of primary PDAC organoids can accurately predict in vivo
treatment efficacy in mice and humans. This approach will be validated on mouse models of PDAC, on primary
patient samples in the adjuvant treatment setting, and on primary patient samples in the metastatic treatment
setting. The proposed development of dynamic, single-cell assessment techniques to monitor drug response in
multiple cell types within intact mouse and human PDAC organoids holds great promise for rational drug
development and treatment planning that could ultimately reduce toxicities and improve outcomes in patients.
胰腺导管腺癌(PDAC)是一种侵袭性疾病,
所有癌症中预后最差(5年生存率为7%),在美国每年有超过40,000人死亡。标准型-
PDAC的护理外治疗包括手术和化疗。许多患者接受化疗后,
手术(“辅助治疗”),以改善无进展生存期。大约45-55%的患者存在
转移性疾病,如果耐受,立即开始化疗。不幸的是,
与化疗相关的毒性,并且没有工具来确定患者是否会从化疗中获益。
毒性更强的药物和毒性更弱的药物。此外,没有合理的系统将每个患者与
最有前途的抗癌新药最后,对于PDAC几乎没有有效的药物,因此,
加速药物开发的需求。因此,迫切需要改善PDAC患者的护理
通过降低毒性、合理的治疗计划和新药开发。
该提案的目标是开发新的细胞水平成像技术来预测治疗反应
在个体PDAC患者中,使用维持在3D培养物中的患者肿瘤的大悬液,
(“类器官”)。这种非侵入性光学代谢成像(OMI)方法利用了内源性荧光
代谢辅酶NADH和FAD的强度和寿命,以在单细胞水平上成像药物反应
在完整的3D样本中的所有细胞中。这种单细胞分析允许异质性药物反应被
在肿瘤细胞和基质细胞的治疗时间过程中监测。这对于评估治疗很重要
在PDAC的高度异质性和基质微环境中的疗效。原发性肿瘤的应用
来自患者自身肿瘤的类器官也保持了细胞间的通讯,3D结构,
肿瘤-基质相互作用,这对准确评估药物反应至关重要。我们的初步数据显示,
原发性PDAC类器官中的OMI(1)可准确预测小鼠体内药物反应,(2)可识别药物
其有效地靶向肿瘤成纤维细胞用于基质重组和改善药物递送。我们还
在6名PDAC患者中进行人体试验的可行性。这个新的平台提供了巨大的潜力(1)
在相关患者样本上快速测试新药方案,从而加速PDAC药物开发,以及
(2)提供个性化的药物筛选,为每位患者确定最有效和毒性最小的治疗方法。
该提案将检验以下假设:原发性PDAC类器官的OMI可以准确预测体内
在小鼠和人类中的治疗功效。该方法将在PDAC小鼠模型上、在原发性
辅助治疗环境中的患者样本和转移性治疗中的主要患者样本
设置.建议开发动态单细胞评估技术,以监测药物反应,
完整小鼠和人类PDAC类器官中的多种细胞类型为合理药物带来了巨大希望
开发和治疗计划,最终可以减少毒性和改善患者的结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Melissa Caroline Skala其他文献
Melissa Caroline Skala的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Melissa Caroline Skala', 18)}}的其他基金
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
用于视网膜成像的光热光学相干断层扫描的开发和验证
- 批准号:
10550200 - 财政年份:2022
- 资助金额:
$ 24.64万 - 项目类别:
Development and Validation of Photothermal Optical Coherence Tomography for Retinal Imaging
用于视网膜成像的光热光学相干断层扫描的开发和验证
- 批准号:
10380391 - 财政年份:2022
- 资助金额:
$ 24.64万 - 项目类别:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
胰腺癌类器官的光学成像用于药物开发和个性化治疗
- 批准号:
9388210 - 财政年份:2017
- 资助金额:
$ 24.64万 - 项目类别:
Optical imaging of pancreas cancer organoids for drug development and personalized treatment
胰腺癌类器官的光学成像用于药物开发和个性化治疗
- 批准号:
10223218 - 财政年份:2017
- 资助金额:
$ 24.64万 - 项目类别:
(PQ7) Quantitative in vivo optical imaging of tumor heterogeneity
(PQ7) 肿瘤异质性的定量体内光学成像
- 批准号:
9323359 - 财政年份:2016
- 资助金额:
$ 24.64万 - 项目类别:
Cellular level optical metabolic imaging to predict drug response in cancer
细胞水平光学代谢成像预测癌症药物反应
- 批准号:
9298127 - 财政年份:2014
- 资助金额:
$ 24.64万 - 项目类别:
Cellular level optical metabolic imaging to predict drug response in cancer
细胞水平光学代谢成像预测癌症药物反应
- 批准号:
9767107 - 财政年份:2014
- 资助金额:
$ 24.64万 - 项目类别:
Cellular level optical metabolic imaging to predict drug response in cancer
细胞水平光学代谢成像预测癌症药物反应
- 批准号:
9138626 - 财政年份:2014
- 资助金额:
$ 24.64万 - 项目类别:
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
用于监测癌症耐药性的功能光学相干断层扫描
- 批准号:
8128195 - 财政年份:2010
- 资助金额:
$ 24.64万 - 项目类别:
Functional Optical Coherence Tomography for Monitoring Drug Resistance in Cancer
用于监测癌症耐药性的功能光学相干断层扫描
- 批准号:
8307913 - 财政年份:2010
- 资助金额:
$ 24.64万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 24.64万 - 项目类别: